Introduction
The chemotherapeutic agent Cisplatin (cis-diamminedichloroplatinum(II)) is particularly eective against testicular and ovarian carcinoma (for a recent review see Einhorn, 1997) although its clinical success is limited by recurrent drug resistant disease. The ability of cisplatin to react with DNA to form intra-and interstrand crosslinks is generally considered to be the basis of its therapeutic eect. Consistent with this view, factors which diminish the level of cisplatin reaction with DNA reduce the toxicity of the drug. Alterations in drug uptake or eux and intracellular quenching of cisplatin molecules by reaction with active thiol compounds all contribute to cisplatin resistance by reducing the burden of DNA damage (for recent reviews see: Mello et al., 1998; Jamieson and Lippard, 1999) .
In addition to these protective mechanisms, DNA repair may also in¯uence cellular sensitivity. Removal of potentially lethal DNA lesions may promote cell survival (Johnson et al., 1994) . In particular, a reduced nucleotide excision repair capacity is implicated in the selective cisplatin sensitivity of testicular carcinoma cells (KoÈ berle et al., 1999 ). An independent DNA repair pathway, mismatch repair, may also in¯uence the cytotoxicity of cisplatin. In contrast to the ameliorative eects of nucleotide excision repair, mismatch repair potentiates drug lethality. The absence of this error-correcting mechanism is associated with increased cisplatin resistance in several human tumor cell lines. This mirrors their methylation tolerant phenotype in which death resulting from persistent O 6 -methylguanine (O 6 -meGua) or 6-methylthioguanine in DNA is prevented by a defect in the hMSH2, hMLH1, hPMS2 or hMSH6 mismatch repair proteins (for a recent review see O'Driscoll et al., 1998) . Tumor cells with defects in either the hMSH2 or hMSH6 components of the hMutSa mismatch repair complex or in the hMLH1 or hPMS2 constituents of hMutLa mismatch repair heterodimer Aebi et al., 1996; Fink et al., 1998) , are resistant to cisplatin. Consistent with an involvement of this pathway in mediating the cellular response to the drug, hMutSa is able to recognize some cisplatin-DNA adducts (Duckett et al., 1996; Yamada et al., 1997) . One unexplained feature of mismatch repair-related cisplatin tolerance is its association with widely dierent degrees of cisplatin resistance. These range from less than twofold to greater than 50-fold Aebi et al., 1996; Fink et al., 1996; Durant et al., 1999) .
The survival of cells with damaged DNA may also be in¯uenced by cellular functions such as the p53 stress response (for a recent review see Levine, 1997) . The p53 protein accumulates in drug-treated cells and normally increases the rate of transcription of target genes such as p21, Bax, GADD45, and Mdm2. The induced proteins control critical cellular functions including the levels of the p53 protein itself, progression through the cell cycle, and cellular apoptosis. Although methylating drugs can induce the p53 response, cell killing by these agents is independent of the cell's p53 status (Aquilina et al., 1998; d'Atri et al., 1998; Hickman and Samson, 1999) . Cisplatin also induces the p53 response. In this case, however, there is evidence that cell survival may be in¯uenced by p53 although the eects of abrogated p53 function on drug sensitivity are unpredictable (for example : Fan et al., 1994 : Fan et al., , 1995 .
We have investigated the involvement of mismatch repair and p53 in cisplatin sensitivity. Examination of a number of human tumor cell lines which dier in their mismatch repair capacities indicated that mismatch repair status alone is not an accurate predictor of cisplatin resistance. In the case of the widely-studied ovarian carcinoma A2780 cells, we show that mismatch repair defects may facilitate the emergence of cisplatin resistance. The occurrence of mismatch repair defects in drug resistant cells need not imply a signi®cant and direct involvement of mismatch repair in cisplatin cytotoxicity. By disabling mismatch repair or introducing a defective p53 into A2780 cells, the separate contributions of these factors to cisplatin resistance were analysed quantitatively. Defects in either function increased cisplatin resistance. The eects on survival were independent and additive and a defective p53 response was a considerably more signi®cant contributor to drug resistance. The ®ndings have implications for possible mechanisms by which tumors may acquire an intrinsic cisplatin resistance.
Results

Tumor cell lines
The cisplatin resistance of several human tumor cell lines of known mismatch repair capacity was determined. LoVo, SW48, SW620, HT29 and DLD-1 are colorectal carcinoma cell lines. SW620 and HT29 are mismatch repair pro®cient whereas LoVo, SW48 and DLD-1 are respectively defective in the hMSH2, hMLH1 and hMSH6 mismatch repair proteins. DU145 is derived from a prostatic carcinoma and is de®cient in both hMSH3 and hMLH1. DLD-1, SW48, LoVo and DU145 are all highly resistant to the methylating agent N-methyl-N-nitrosourea (Branch et al., 1995; Aquilina et al., 1998) . In contrast, no systematic dierences in cisplatin resistance of repair pro®cient and de®cient cells were apparent (Figure 1 ). In particular, the cisplatin sensitivities of SW620, HT29, LoVo and SW48 were similar. DLD-1 cells were considerably more cisplatin resistant than LoVo, despite sharing a defect in the hMutSa mismatch recognition function. Thus, whereas methylation resistance is a clear indicator of mismatch repair status, it is not possible to identify mismatch repair defective cells by comparing the cisplatin sensitivity of nonisogenic cell lines. This presumably re¯ects the multifactorial nature of cisplatin resistance. In particular, the cell lines we examined are known to dier in their p53 status. For this reason, we examined the separate eects of p53 and mismatch repair status in a series of closely related cell lines.
Variants of A2780 ovarian tumor cells
A2780 is a well-characterized ovarian carcinoma cell line which is pro®cient in mismatch repair and retains an intact p53 response Brown et al., 1993) . A2780 cells are sensitive to cisplatin and are used as a model for the therapeutic eects of the drug. We used clonal derivatives of A2780 to investigate the contributions of mismatch repair and other factors to cisplatin sensitivity.
Mismatch repair defective A2780 cells were isolated by selection for a methylation tolerant phenotype. Brie¯y, a single clone exhibiting a high level of MNU resistance was selected from several independent A2780 cultures. Ten such isolates exhibited an unexpected similarity and a¯uctuation analysis indicated that they were members of a preexisting subpopulation which comprises approximately 10 72 % of the A2780 culture . Three typical clones, A2780MNU1, 2 and 5, which were 4100-fold resistant to MNU (Humbert et al., 1999 and data not shown), did not express detectable hMLH1 or hPMS2 protein by immunoblotting (data not shown, but see below). Extracts of A2780MNU1, 2 and 5 were unable to correct a C/T mispair in the standard mismatch repair assay. In contrast, extracts of the parental A2780 cells which expressed normal levels of hMLH1 were fully mismatch repair pro®cient (Humbert et al., 1999 and below) . A2780MNU1, 2 and 5 were signi®cantly more resistant to cisplatin than their A2780 parental cells. Their D 37 value for the drug was approximately fourfold higher. This compares with the 12-fold higher resistance of the well-characterized A2780CP70 cell line which was included for comparison ( Figure 2a) . The cisplatin sensitivities of A2780MNU1, 2 and 5 were indistinguishable and data for several determinations using the three lines have been combined in Figure 2a . The D 37 value of 21 mM is in the middle of the range reported above for the mismatch repair de®cient tumor cell lines.
The hMLH1 de®ciency of these variants is not the only alteration relevant to cisplatin sensitivity. Un- expectedly, A2780MNU1, 2 and 5 were also found to contain a heterozygous p53phe172 mutation. This mutation is associated with complete loss of detectable p53 response following exposure to ultraviolet light or cyclohexyl chloroethylnitrosourea (CCNU) . This defect extended to cisplatin. Thus, p53 levels were high in untreated A2780MNU1 cells and were not increased by cisplatin treatment ( Figure  2b ). Treatment with either equitoxic or equimolar concentrations of cisplatin did not induce expression of the p21, Bax, and Mdm2 proteins in A2780MNU1 (Figure 2b ). The same constitutively high levels of p53 and the absence of induction of its downstream targets following drug treatment were also observed in A2780MNU 2 and 5 (data not shown). The A2780 parental cells mounted a normal response to cisplatin and their constitutively low levels of p53 protein were increased together with those of the p21, Bax and Mdm2 proteins after cisplatin treatment. Thus, in addition to an hMLH1 defect, the p53 stress response, which is normally activated by cisplatin, is impaired in A2780MNU1, 2 and 5.
Separate and additive effects of mismatch repair and p53 response in A2780
The eects of mismatch repair de®ciency and abrogated p53 response on cisplatin sensitivity were examined separately. Two approaches were taken. In the ®rst, either an hMLH1 or a p53 defect was introduced independently into A2780 cells and the sensitivity to cisplatin was then determined. Two clonal derivatives of A2780, designated A2780SC1 and SC2, were isolated. A2780SC1, SC2 and the parental A2780 cells exhibited an identical sensitivity to several agents including MNU, 6-TG and CCNU . A methylation tolerant variant was selected from both A2780SC1 and SC2 (A2780MNU1-A and A2780MNU1-B). The properties of A2780MNU1-A and A2780MNU1-B were closely similar. For brevity, only A2780SC1 and its tolerant derivative A2780MNU1-A will be described further. Expression of hMLH1 is much reduced (490%) in the methylation tolerant A2780MNU1A cells . Importantly, both A2780SC1 and A2780MNU1-A retain a functional p53 response following treatment with cisplatin. The low constitutive levels of the p53 protein were markedly increased by cisplatin treatment in A2780SC1 and A2780MNU1-A (Figure 3a) . The same treatment also induced expression of the p21 and Bax proteins ( Figure 3a and data not shown). Retention of a functional p53 stress response in the methylation tolerant A2780MNU1-A clone was expected and is consistent with previous ®ndings that resistance to methylating agents is independent of the cell's p53 status. The greatly reduced expression of the key hMLH1 mismatch repair protein combined with a wild-type p53 response in A2780MNU1-A was not associated with a signi®cant increase in cisplatin resistance (Figure 3b ) and the survival of A2780MNU1A cells was indistinguishable from that of the parental A2780SC1 cells. Both A2780SC1 and A2780MNU1A exhibited poor cloning eciencies and colonies tended to detach from the plates. This necessitated the use of 96-well plates in survival determinations. The sensitivity of these measurements is likely to be lower and small dierences in cisplatin resistance may have been obscured. For this reason, we conclude only that the methylation tolerant A2780MNU1A cells, which retain functional p53, do not share the extensive cisplatin resistance of A2780MNU1 and its related clones. These data indicate that a signi®cant degree of cisplatin resistance in A2780MNU1, 2 and 5 is due to factors other than defective mismatch repair.
The p53 response of A2780SC1 was inhibited by introducing a dominant negative mutant p53 (p53val135). The presence of p53val135 had the anticipated eect on the p53 response (Figure 3c ). p53 protein was constitutively expressed at levels equivalent to those seen in induced A2780SC1 cells. These levels were increased only slightly by cisplatin Extracts prepared after a further 24 h growth in drug-free medium were separated by PAGE. After transfer to nitrocellulose, ®lters were probed with anti-p53, -Bax, -p21, and -Mdm2 as shown treatment. p21 expression was extremely low in the p53val135 containing cells and was also increased slightly by cisplatin treatment. The induced level was, however, lower than the constitutive expression in the parental A2780SC1 cells. Comparable results were obtained when p53val135 was expressed in A2780MNU1A cells (data not shown). The mismatch repair pro®cient, A2780 p53val135 cells were approximately 2.5-fold more resistant to cisplatin than A2780 (Figure 3b ). Similar increases in cisplatin resistance are conferred on A2780 cells by other dominant negative p53 variants (Eliopoulos et al., 1995; Vasey et al., 1996) . When p53val135 was expressed in the hMLH1-de®cient A2780MNU1A, the resulting cells were fourfold more resistant than A2780sC1 (Figure 3b ) and were comparable to A2780MNU1, 2 and 5 in this regard. Thus, the resistance of A2780MNU1, 2 and 5 can be accounted for by additive eects of their defective p53 responses and mismatch repair. Of the two determinants of resistance, loss of the p53 response has a more signi®cant impact than loss of mismatch repair.
Correction of hMLH1 defect in A2780MNU1
In a second approach, we sought to correct the mismatch repair defect of A2780MNU1. This was achieved by two dierent strategies which produced similar results. In the ®rst, a previously silent hMLH1 gene in A2780MNU1 cells was reactivated by treatment with the DNA demethylating agent 5-azadeoxycytidine. In the second, the mismatch repair capacity of A2780MNU1 cells was restored by transfection and stable expression of hMLH1 cDNA.
Expression of hMLH1 was activated by treatment of A2780MNU1 cells with AzadC. The level of hMLH1 protein increased signi®cantly but was still less than that of A2780 cells. Direct determination by immunoblotting of extracts prepared from clonal isolates of the reactivated population indicated that the hMLH1 expression was 10 ± 20% of that in A2780SC1 ( Figure  4a ). The extent of hMLH1 expression was, however, sucient to sensitize the cells to MNU by 450-fold (data not shown). In contrast to the eects on MNU tolerance, reexpression of the silent hMLH1 gene in A2780MNU1AdC cells was associated with only a slight sensitization ± 1.3-fold ± to cisplatin ( Figure  4b) .
In a second series of experiments, A2780MNU1 cells were transfected with a vector containing hMLH1 cDNA under the control of a cytomegalovirus promoter. After antibiotic selection, hMLH1 protein was detectable by immunoblotting extracts of the cDNA transfected cells. hMLH1 expression by clonal isolates of this population was comparable to the parental A2780 cells (Figure 4c ). Extracts prepared from an hMLH1-expressing clone (A2780pMLH1.A) were tested for the ability to carry out mismatch repair. The level of hMLH1 expression in A2780pMLH1.A was sucient to restore C/T mispair correction to wildtype, or better, levels (Figure 4d ). A2780pMLH1.A cells were extremely sensitive to MNU and their sensitivity was indistinguishable from that of A2780MNU1AdC (data not shown). In contrast, this high level of expression of hMLH1 was not associated with extensive cisplatin sensitivity. A2780pMLH1.A cells were only 1.3-fold more sensitive to cisplatin than A2780MNU1. The extent of sensitization was indistinguishable from that seen in A2780AdC1 (Figure 4b) . Thus, restoration of MNU sensitivity and mismatch repair activity by expression of an endogenous or exogenous hMLH1 was associated with only a minor (1.3-fold) reduction in cisplatin resistance.
In summary, hMutLa-de®cient A2780MNU1,2 and 5 variants were signi®cantly (fourfold) more resistant Oncogene Mismatch repair and p53 in cisplatin resistance P Branch et al to cisplatin than their repair pro®cient parental A2780 cells. The resistant cells were representatives of a drug naõÈ ve subpopulation with both hMLH1 and p53 de®ciencies. The responses of A2780 clones in which mismatch repair defects and mutated p53 were introduced separately or together indicates that defective mismatch repair is a minor determinant of cisplatin resistance. An abrogated p53 response contributes a more pronounced tolerance to the drug. The eects of mismatch repair and p53 defects on drug resistance are independent and additive.
Discussion
Mismatch repair defects were not associated with a predictable degree of cisplatin resistance among our panel of human tumor cell lines. This is in contrast to the eects on methylating agent sensitivity in which a high level of resistance to persistent O 6 -meGua is diagnostic for loss of mismatch repair. Cisplatin resistance is multifactorial. We therefore considered other determinants of cisplatin responsiveness in a wellstudied model cell line. Methylation tolerant variants selected from A2780 were, as anticipated, defective in mismatch repair. They were also found to express mutated p53. The selection of simultaneous mismatch repair and p53 defects in methylation tolerant cells was unprecedented in our experience. Methylation tolerant cells have been isolated from p53 positive or negative starting cells (Goldmacher et al., 1986; Branch et al., 1993; Aquilina et al., 1995) and tolerance is known to be unaected by the cell's p53 status (Aquilina et al., 1998; Hickman and Samson, 1999) . This apparent anomaly was resolved by the demonstration of a subpopulation of A2780 cells which are both de®cient in hMLH1 expression and heterozygous for the p53phe172 mutation. The existence of this subpopulation must be taken into account in any analysis of drug resistant variants of this model cell line.
The doubly hMLH1/p53 defective MNU tolerant cells were markedly resistant to cisplatin. A subpopulation of cisplatin resistant A2780, estimated to be around 10 76 per cell, has been reported previously (McLaughlin et al., 1991) . It seems likely that during the ensuing 10 years of continuous propagation, this population has expanded to around 10 74 per cell. This is consistent with the higher plating eciency and generally better growth of the hMLH1/p53 de®cient cells. A2780 is a widely used model for cisplatin responsiveness in ovarian tumor cells and many drugresistant A2780 variants have been isolated (Godwin et al., 1992) . It seems probable that many, if not all, these variants were derived from the same spontaneously arising subpopulation and contain both a silent hMLH1 and a mutated p53 gene. Several observations provide compelling circumstantial evidence for this possibility. Firstly, a subclone of the cisplatin resistant A2780/C30 variant contains the same heterozygous p53phe172 mutation as A2780MNU1 (Siddik et al., 1998) . this position is not a recognized mutational hotspot and this particular change is uncommon among reported p53 mutations (Hernandez-Boussard et al., 1999) . Secondly, A2780MNU clones 1, 2 and 5 resemble the highly cisplatin resistant A2780CP70 cells which are also defective in hMLH1 expression and fail to induce p21 after drug treatment . A2780CP70 cells were isolated from A2780 by extensive exposure to cytotoxic cisplatin concentrations and the hMLH1 and p53 defects are consistent with their derivation from the subpopulation. A2780CP70 are more cisplatin Mismatch repair by extracts of hMLH1-expressing A2780MNU1 cells. Extracts prepared from A2780, A2780MNU1 and A2780pMLH1A were assayed for the ability to correct a C/T mismatch and restore an MluI restriction endonuclease site in a standard nicked circular duplex DNA substrate. Following incubation of substrate and extract as indicated, DNA was digested with MluI and the products analysed on 0.8% agarose gels in the presence of ethidium bromide. The upper band is unit length substrate in which the mismatch remains. The lower band (arrowed) corresponds to corrected molecules resistant than the A2780MNU clones and contain additional alterations ± such as increased glutathione levels (Godwin et al., 1992) which reduce the level of DNA platination they sustain. These changes contribute to their overall cisplatin resistance and may have been selected after the p53 and hMLH1 defects as a result of further prolonged exposure to cisplatin. Thirdly, a panel of resistant A2780 cells which were selected by multiple exposures to cisplatin, contained a silent hMLH1 gene which could be reactivated by azadeoxycytidine treatment (Strathdee et al., 1999) , and were also defective in p53-dependent p21 induction .
Because A2780 is a widely used model for the eects of drug treatment on ovarian cancer cells, it is important to establish the relative contributions of the mismatch repair and p53 de®ciencies to cisplatin susceptibility. The approach of examining the separate eects on cisplatin resistance of either a mismatch repair or a dominant negative p53 mutation in A2780 indicates that the p53 response is the major determinant of cisplatin sensitivity. Defective mismatch repair, conferred by silencing of hMLH1 expression, contributes a much more modest increment in drug resistance. hMLH1-defective A2780MNU1A cells were not detectably more resistant to cisplatin than their repair pro®cient A2780SC1 parents. This indicates that any contribution of defective mismatch repair to cisplatin resistance is likely to be small. It is consistent with the observed modest increases in drug sensitivity following correction of repair defects in tumor cell lines by chromosome transfer . This conclusion is also compatible with the small decrease in cisplatin resistance which accompanied reactivation of hMLH1 by azadeoxycytidine treatment or complete restoration of repair capacity in A2780MNU1 by expression of the hMLH1 cDNA. To our knowledge, this is the ®rst successful complementation of an hMLH1 defect of a human tumor cell line by expression of the cDNA. A signi®cantly higher degree of cisplatin sensitization is associated with correction of mismatch repair defect of A2780CP70 by transfer of an active copy of chromosome 3 (Durant et al., 1999) . We have no explanation for this discrepancy but we note that, whereas hMLH1 cDNA expression speci®cally corrects the repair defect, many additional genes which may in¯uence cisplatin sensitivity could be expressed from a transferred chromosome. In summary, our data indicate that a mutated p53 and defective mismatch repair in¯uence cisplatin sensitivity independently and to dierent extents.
Selection of cisplatin resistant variants of other ovarian carcinoma models indicates that the properties of A2780 are not atypical. A highly cisplatin resistant variant of A2008 ovarian carcinoma cells (2008/A) was also defective in hMLH1 expression . Signi®cantly, the degree of cisplatin resistance in 2008/ A cells was substantially greater than the modest level associated with mismatch repair defects in tumor cells which had not undergone cisplatin selection. These observations are consistent with the presence of multiple mutations (or epigenetic changes) which enhance cisplatin drug resistance in A2008/A. It is noteworthy that loss of expression of hMLH1 occurs in both the A2780 and A2008 variants. The hMLH1 gene is particularly susceptible to spontaneous epigenetic silencing in cultured cells and tumors (Herman et al., 1998) . Loss of the replication editing function of mismatch repair confers a signi®cant mutator phenotype. Potentially advantageous mutations will arise in these mismatch repair de®cient cells at elevated rates. Cells with mutations which confer a growth advantage will undergo clonal expansion during propagation in vitro and variants which have acquired growth enhancing mutations which also aect drug sensitivity, such as p53, will be selected by drug treatment. Thus, the role of defective mismatch repair may simply be to facilitate the emergence of cells with mutations which decrease drug sensitivity. This, rather than a direct involvement in cisplatin resistance, may explain the increased frequency of hMLH1 loss in ovarian carcinomas (Strathdee et al., 1999) . Any direct involvement of mismatch repair proteins in recognition or signaling DNA damage appears to be of more limited signi®cance.
Notwithstanding the exact mechanism by which cells accumulate multiple defects associated with cisplatin resistance, there are two important implications of the relative contributions of defective mismatch repair and p53 mutations. Silencing of hMLH1 appears to be a frequent event. A2780 may be typical and concurrent mismatch repair and growth control mutations common. If this is the case, altered sensitivity of selected variants to other DNA damaging drugs or radiation cannot simply be ascribed to loss of mismatch repair. Thus, the presence of hMLH1 defects in adriamycin (doxorubicin) resistant A2780 cells may be fortuitous. Secondly, chronic exposure to escalating drug concentrations is likely to select cells with alterations in gene expression conferring the highest level of resistance. The relatively minor contribution of defective mismatch repair to cisplatin resistance suggests that other changes are more likely to be associated with clinical failure of cisplatin therapy.
Materials and methods
Cells and cisplatin treatment
Human tumor cell lines LoVo, SW48, SW620, DU145, and DLD-1 from the Imperial Cancer Research Fund cell collection were cultured as previously described Branch et al., 1995 and A2780CP70 cells kindly provided by Dr R Brown, (University of Glasgow, UK) were grown in MEM supplemented with 10% fetal calf serum. Selection of the methylation tolerant clones A2780MNU1, 2 and 5; the SC1 and SC2 subclones of A2780 and their methylation tolerant variants A2780MNU1-A and A2780MNU1-B has been described previously . Construction of the A2780 variant expressing a transfected dominant negative p53: (p53val135; Michalovitz et al., 1990) and genomic DNA sequencing of the p53 gene of A2780 and its methylation tolerant variants have also been described . All cells were maintained in humidi®ed incubators containing 5% CO 2 .
Cisplatin (Sigma) was dissolved in a minimal volume of DMSO and diluted in growth medium prior to use. For clonal survival assays, cells were allowed to attach to 10 cm dishes for at least 2 h prior to treatment with the drug. After 1 h exposure, the medium was replaced and surviving colonies were stained after 7 ± 10 days growth. Survival of cisplatin-treated A2780SC1, A2780SC2 and their methylation tolerant counterparts, A2780MNU1A and A2780MNU1B, was determined in 96-well plates. Cisplatin-treated cells were plated at appropriate densities in 96-well plates. After 7 ± 10 days growth, the plating eciencies were calculated and cell survival was estimated from the Poisson distribution. All survival determinations were performed at least twice. Comparative sensitivity was determined from the D 37 values.
A2780MNU1 cells in which hMLH1 was reexpressed were isolated following treatment with azadeoxycytidine (AzdC) or expression of a transfected cDNA. For reactivation, exponentially growing cells were treated with 3 mM AzdC at 8 ± 10 day intervals. A total of three treatments were carried out. After the ®nal treatment, several clonal isolates of treated cells were examined for expression of hMLH1 by immunoblotting. A2780AdC1 was among the clones which expressed the highest level of hMLH1.
For transfection, hMLH1 cDNA (Buermeyer et al., 1999 ) (kindly provided by Dr M Liskay, University of Oregon, USA) cloned into the pBK-CMV vector (Stratagene) was introduced into A2780MNU1 cells by calcium phosphate precipitation. G418 (700 mg/ml)-resistant transfectant cells were selected by growth for 10 ± 12 days. Clonal isolates were screened for expression of hMLH1 by immunoblotting. One such isolate, A2780pMLH1.A, was selected for further analysis because it expressed levels of hMLH1 which were close to those of parental A2780 cells.
Immunoblotting
Antibodies against p53 (FL-393) and p21 were obtained from Calbiochem (La Jolla, CA, USA); against Bax, Mdm2, hMLH1 (Clone G168-728), and hPMS2 (mAB A16-4) from Pharmingen (Los Angeles, CA, USA).
Growing cells were treated with cisplatin at appropriate concentrations and harvested 24 h later. Extracts were prepared by suspending the cell pellet in PBSA containing 1% NP40, 10 mM NaF, 10 mg/ml each of leupeptin and aprotinin, 1 mM AEBSF. Samples (50 mg protein) were denatured and separated on 7.5 or 12% SDS polyacrylamide gels. Proteins were transferred to nitrocellulose and probed with appropriately diluted antibody (1 mg/ml for the monoclonal anti-hMLH1, -PMS2 and -p21; 2 mg/ml for anti-Mdm2; 0.1 mg/ml for anti-Bax and 2.5 mg/ml for antip53). After appropriate washing, blots were developed using the ECL detection system (Amersham).
Mismatch repair assay
The substrate for the in vitro mismatch repair assay contains a single T/C mismatch 580 bp 5' of a unique single-strand interruption in the T-containing strand. Mismatch repair by cell extracts was analysed essentially as described in Hampson et al. (1997) . Brie¯y, cell extracts were incubated (60 min, 378C) with the duplex circular mismatched substrate. Reactions were terminated, DNA was recovered and digested with the MluI restriction endonuclease. Nick-directed correction of the mispaired T to restore a G/C base pair reconstructs a site for cleavage by MluI. Since the substrate contains a second MluI site 567 bp distant, corrected molecules are cleaved into two products (3.9 kbp and 0.57 kbp) whereas uncorrected molecules which retain the single MluI site, remain unit length (4.47 kbp). The 3.9 and 4.47 kbp linear duplexes were resolved by electrophoresis in 0.8% agarose gels in 40 mM Tris-acetate, pH 8.0, 1 mM EDTA containing ethidium bromide. Separated reaction products were viewed under short-wave ultraviolet light.
